Armatinib with or without brain radiation for EGFR lung cancer
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old
- Your lung cancer is non-small cell lung cancer and has an EGFR mutation (exon 19 deletion or exon 21 L858R)
- You have brain metastases that are mostly not causing major symptoms (headache/nausea/seizures controlled with stable medicines for at least 3 days)
- Brain MRI shows 1–10 brain or brainstem lesions that can be measured, and you can have an MRI scan
- You have not had previous EGFR medicines (EGFR-TKI), and you haven’t had other study drugs or certain brain radiation recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
This Phase 3 study tests whether giving brain radiation early or later, along with almonertinib (a targeted pill), works better for people with EGFR-mutated non-small cell lung cancer that has a small number of brain metastases. It aims to control brain disease while checking safety and effectiveness in a carefully selected group.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.